In male mice with tibialis-anterior muscle injury, cinchonidine administered in drinking water at a reported 25 mg/kg for six days was associated with smaller regenerating muscle fiber diameters. The authors reported no significant changes in liver histology or measured blood biochemistry over this course; these observations do not establish general safety. [1]
In a male mouse MCAO/reperfusion model, cinchonidine reduced acute infarct volume when administered at 5 or 10 mg/kg before ischemia or at 10 mg/kg one hour after reperfusion. The 10 mg/kg regimens also reduced brain edema at 24 hours. The study did not establish long-term benefit, pharmacokinetics or brain penetration. [2]
Reduced regeneration-associated muscle fiber diameter in injured mice
Animal study · BaCl2-injured tibialis anterior muscle of eight-week-old male C57BL/6 mice [1]
Following cinchonidine exposure, histology showed a shift toward smaller regenerating fiber diameters. The selected data assess muscle regeneration morphology; they do not establish a muscle-strength effect in humans. Liver histology and measured blood biochemistry showed no significant differences according to the authors.
Conditions shared by the study groups
- Route
- Drinking water
- Treatment course
- Started the day after tibialis-anterior injury; treatment for 6 days
- Vehicle
- Drinking water
- Cinchonidine after muscle injury
- Model: Eight-week-old male C57BL/6 mice; four different mice per group in Figure 5B
- Reported limits: Water intake, achieved exposure and dosing frequency were not specified; the reported dose is not rewritten as mg/kg/day.
Methods and source locations
Compound reported in the paper: Cinchonidine; Compound label in the paper: CD
Injury-model histology and limited toxicity observations only.
Figure 5A–D/caption; Materials and Methods, Animals; Results, CD inhibits satellite cells activity and lowers muscle regeneration capacity
Diameter distribution of regenerating tibialis-anterior muscle fibers: H&E histology and diameter-bin distribution; four different mice per group. Figure 5B has no exact summary diameter estimate or inferential annotation. — Figure 5A–D/caption; Materials and Methods, Animals; Results, CD inhibits satellite cells activity and lowers muscle regeneration capacity
Liver histopathology and ALT, AST, ALP, glucose, total cholesterol and BUN: Figure 5C–D; no numeric assay values estimated from bars. This is not a comprehensive safety evaluation. — Figure 5A–D/caption; Materials and Methods, Animals; Results, CD inhibits satellite cells activity and lowers muscle regeneration capacity
Cinchonidine after muscle injury · Figure 5A–D/caption; Materials and Methods, Animals; Results, CD inhibits satellite cells activity and lowers muscle regeneration capacity
Reduced acute ischemic lesion burden in male mice
Animal study · Male C57BL/6 mice, 6–8 weeks, transient MCAO/reperfusion; separate acute histology cohort [2]
Cinchonidine reduced infarct volume at 24 h after reperfusion. At 10 mg/kg, both pre-treatment and post-treatment also reduced edema. Results remain limited to acute injury in male mice; pharmacokinetics, brain penetration and long-term benefit were not established.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Vehicle
- PEG400:DMSO, 9:1 (v/v); 100 μL/mouse
- Pre-treatment 5 mg/kg
- Model: Male C57BL/6 mice, 6–8 weeks; acute histology cohort, n = 8/group
- Treatment course: 1 h before MCAO
- Reported limits: One timed administration is described; no repeated dosing schedule is specified.
- Pre-treatment 10 mg/kg
- Model: Male C57BL/6 mice, 6–8 weeks; acute histology cohort, n = 8/group
- Treatment course: 1 h before MCAO
- Reported limits: One timed administration is described; no repeated dosing schedule is specified.
- Post-treatment 10 mg/kg
- Model: Male C57BL/6 mice, 6–8 weeks; acute histology cohort, n = 8/group
- Treatment course: 1 h after reperfusion
- Reported limits: One timed administration is described; no repeated dosing schedule is specified.
Methods and source locations
Compound reported in the paper: Cinchonidine; Compound label in the paper: CD
Acute histological outcome; not clinical efficacy or demonstrated BBB penetration.
Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations
Edema-corrected infarct volume as percentage of contralateral hemisphere: TTC histology at 24 h after reperfusion; mean ± SEM, n = 8/group. No exact bar values inferred. — Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations
Brain edema ratio: Figure 1D; mean ± SEM, n = 8/group. No exact bar values inferred. — Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations
Pre-treatment 5 mg/kg · Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations
Pre-treatment 10 mg/kg · Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations
Post-treatment 10 mg/kg · Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations